Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration
Sood S, Mandell J, Watane A, Friedman S, Parikh R. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology 2022, 140: 716-723. PMID: 35708679, PMCID: PMC9204613, DOI: 10.1001/jamaophthalmol.2022.1819.Peer-Reviewed Original ResearchConceptsRanibizumab port delivery systemPort Delivery SystemBevacizumab injectionIntravitreal ranibizumabNeovascular AMDBimonthly injectionsIntravitreal anti-vascular endothelial growth factor injectionsAnti-vascular endothelial growth factor injectionsIntravitreal anti-VEGF injectionsEndothelial growth factor injectionsTotal direct medical costsAnti-VEGF injectionsIntravitreal bevacizumab injectionGrowth factor injectionsDirect medical costsAge-related macularMedicare reimbursement ratesAflibercept injectionsNeovascular AgeFactor injectionsIntravitreal injectionMacular degenerationMAIN OUTCOMERanibizumabMedical costs